This is not only because intracellular cholesterol flux is so critical for the invasive behavior of cancer cells and cancer progression in general, but also because many cholesterol-regulating drugs, such as HMGCR inhibitors (statins), cholesteryl ester transfer protein (CETP) inhibitors, and niacin derivatives have already been developed and are used clinically for other disorders such as hypercholesterolemia. The gene discussed is HMGCR; the disease is cancer.